Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine

Next Previous
Trial Profile

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ramucirumab (Primary) ; Paclitaxel
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RAINBOW
  • Sponsors Eli Lilly and Company; ImClone Systems

Most Recent Events

  • 07 Nov 2025 According to a HanchorBio media release, data from this trial will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held November 5-9, 2025, in National Harbor, Maryland.
  • 03 Jul 2021 Results of Exploratory, post-hoc analysis from the RAINBOW trial reports efficacy, safety, and biomarker outcomes from ramucirumab and paclitaxel treatment in patients with and without liver metastasis at baseline, presented at the 23rd World Congress on Gastrointestinal Cancer
  • 23 Dec 2020 Results (n=140) of an exploratory analysis from a sub-group of advanced gastric cancer patients from Japan assessing quality of life associated with ramucirumab published in the Clinical Drug Investigation

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top